Keywords
Observational study
Treatment
Genotype
Sustained virologic response
How to Cite
Abstract
Background: Recently, the management of patients chronically infected with the hepatitis C virus has progressed, including second generation direct-acting antivirals (DAA) that have potential to clear infection in most patients, especially genotype 1-infected patients. Objectives: Evaluate the sustained virologic response (SVR) of Hepatitis C treatment with second-generation DAAs made available by the Ministry of Health in follow-up patients of a São Paulo health service. Methods: This was a retrospective observational study, based on secondary data obtained from GAL and MEDEX systems. Briefly, 615 convenience samples were analyzed of patients who underwent second-generation DAAs treatment from June 2016 to April 2018. Demographic and clinical data were also analyzed. Results: SVR was observed in 600 treated patients (97.6%). Further, 98.4% and 94.7% of genotype 1 and genotype 3 patients, respectively, responded to treatment (P = 0.02). Among patients who did not respond to treatment, 93.3% were male, naive treatment and were treated for 12 weeks, except one genotype 1, HIV-coinfected patient who received treatment for 24 weeks. Conclusions: A high rate of SVR was found for Hepatitis C treatment with second-generation DAAs. SVR was significantly reduced in male and genotype 3-infected patients, although it still exceeded 90%. Further, HIV coinfection showed no association with reduced SVR rates (p=0.98).
References
2. Amaku M, Burattini MN, Coutinho FAB, Lopez LF, Mesquita F, Naveira MC, et al. Estimating the size of the HCV infection prevalence: a modeling
approach using the incidence of cases reported to an official notification system. Bull Math Biol. 2016;78(5):970-90.
3. Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol. 2009;43(7):686-91.
4. Iacomi F, Iannicelli G, Franceschini A, Migliorisi P, Rosati S, Piselli P, et al. HCV infected prisoners: Should they be still considered a difficult to treat
population? BMC Infect Dis. 2013;13:374.
5. Pawlotsky JM. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis. 2014;34(1):22-9.
6. Cheinquer H, Sette H Jr, Wolff FH, de Araujo A, Coelho-Borges S, Soares SRP, et al. Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil. Ann Hepatol. 2017;16(5):727-33.
7. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-64.
8. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8(4):212-23.
9. European Association for the Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199-236.
10. Zhang J, Nguyen D, Hu KQ. Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies. N Am J Med Sci. 2016;9(2): 47-54.
11. Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkom K, Rojter S, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-
infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatol. 2016;64(2): 370-80.
12. Höner Zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, et al. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in areal-world setting. United European Gastroenterol J. 2018;6(2):213-24.
13. Lanini S, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, et al. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. BMC Infect Dis. 2018;18(1):223.
14. Ministério da Saúde (MS). Secretaria de Vigilância em Saúde. Departamento de DST, Aids e Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções/ Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais. Brasília: MS; 2015. 101p. Available at http://bvsms.saude.gov.br/bvs/publicacoes/protocolo_clinico_diretrizes_hepatite_co_coinfeccoes. pdf. Acessed on: 14.set.2019.
15. Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Pontarolo R. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther. 2016;41(5):478-85.
16. Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Muzzillo DA, et al. Ledipasvir/sofosbuvir with or without ribavirin for the treatment
of chronic hepatitis C genotype 1: a pairwise meta-analysis. J Gastroenterol Hepatol. 2017;32(4):749-55.
17. Ferreira VL, Borba HHL, Wiens A, Pedroso MLA, Radunz VFC, Ivantes CAP, et al. Effectiveness and tolerability of directacting antivirals for chronic hepatites C patients in a Southern state of Brazil. Braz J Infect Dis. 2018;22(3):186-92.
18. Martins RMB, Teles SA, Freitas NR, Motta-Castro AR, Souto FJ, Mussi A, et al. Distribution of hepatitis C virus genotypes among blood donors from
mid-west region of Brazil. Rev Inst Med Trop Sao Paulo. 2006;48(1):53-5.
19. Lopes CLR, Teles SA, Espirito-Santo MP, Lampe E, Rodrigues FP, Motta-Castro AR, et al. Prevalence, risk factors and genotypes of hepatitis C virus infection among drug users, Central-Western Brazil. Rev. Saude Publica. 2009;43(1):43-50.
20. Carvalho AC, Junior JLP, Silva MFO, Neto SGS. Perfil genotípico da hepatite C em um laboratório público do estado do Piauí. R. Interd. 2014;7(3):55-60.
21. Naveira MCM, Almeida EC, Cattapan E, Fernandes N, Gomes JN, Graner B, et al. New antivirals for hepatitis Cin Brazil: preliminary effectiveness
analysis with current national databases. Ann Hepatol. 2016;15(6):997.
22. Medeiros T, Salviato CM, do Rosario NF, Saraiva GDN, Esberard EBC, Almeida JR, et al. Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience. Int J Clin Pharm. 2017;39(6):1304-11.
23. Ministério da Saúde (MS). Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções / Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das
Hepatites Virais. Brasília: MS; 2019. 68 p. Available at http://www.aids.gov.br/pt-br/pub/2017/protocolo-clinico-e-diretrizesterapeuticas-para.hepatite-c-e-coinfeccoes. pdf. Acessed on: 21.ago.2019.
24. Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, et al. Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV–coinfected individuals: Results from the German Hepatitis C Cohort (GECCO-01). Clin Infect
Dis. 2016;63(10):1320-4.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2020 Adriana Parise Compri, Vanessa Cristina Martins Silva, Marcilio Figueiredo Lemos, Isabel Takano Oba, Regina Célia Moreira